Literature DB >> 9850918

Evolution of Alzheimer's disease related cortical lesions.

H Braak1, E Braak, J Bohl, H Bratzke.   

Abstract

Alzheimer's disease is an immutably progressing dementing disorder. Its major pathologic hallmark is the gradual development of neurofibrillary changes in a few susceptible nerve cell types. The cortical changes do not occur inevitably with advancing age. Once the disease has begun, spontaneous recovery or remissions are not observed. The initial changes develop in poorly myelinated areas of the temporal lobe. The destructive process then follows a predictable pattern as it extends into other cortical areas. Advanced age is not a prerequisite for the evolution of the lesions. Alzheimer's disease is thus an age-related, but not an age-dependent disease. The spread of the neurofibrillary changes resembles the process of cortical myelination, however in reverse order.

Entities:  

Mesh:

Year:  1998        PMID: 9850918     DOI: 10.1007/978-3-7091-7508-8_9

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  49 in total

1.  Cerebrospinal fluid levels of Aβ42 relationship with cholinergic cortical activity in Alzheimer's disease patients.

Authors:  Alessandro Martorana; Zaira Esposito; Francesco Di Lorenzo; Viola Giacobbe; Giulia Maria Sancesario; Giulia Bucchi; Sonia Bonnì; Sergio Bernardini; Roberto Sorge; Giuseppe Sancesario; Giorgio Bernardi; Carlo Caltagirone; Giacomo Koch
Journal:  J Neural Transm (Vienna)       Date:  2012-03-09       Impact factor: 3.575

2.  Aging-related gene expression in hippocampus proper compared with dentate gyrus is selectively associated with metabolic syndrome variables in rhesus monkeys.

Authors:  Eric M Blalock; Richard Grondin; Kuey-chu Chen; Olivier Thibault; Veronique Thibault; Jignesh D Pandya; Amy Dowling; Zhiming Zhang; Patrick Sullivan; Nada M Porter; Philip W Landfield
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

3.  Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists.

Authors:  C K Combs; D E Johnson; J C Karlo; S B Cannady; G E Landreth
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

Review 4.  Nonhuman primate models of Alzheimer-like cerebral proteopathy.

Authors:  Eric Heuer; Rebecca F Rosen; Amarallys Cintron; Lary C Walker
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

5.  Hippocampal disconnection contributes to memory dysfunction in individuals at risk for Alzheimer's disease.

Authors:  Travis R Stoub; Leyla deToledo-Morrell; Glenn T Stebbins; Sue Leurgans; David A Bennett; Raj C Shah
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-19       Impact factor: 11.205

Review 6.  Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease.

Authors:  Elizabeth W Twamley; Susan A Legendre Ropacki; Mark W Bondi
Journal:  J Int Neuropsychol Soc       Date:  2006-09       Impact factor: 2.892

7.  Enriched white matter connectivity networks for accurate identification of MCI patients.

Authors:  Chong-Yaw Wee; Pew-Thian Yap; Wenbin Li; Kevin Denny; Jeffrey N Browndyke; Guy G Potter; Kathleen A Welsh-Bohmer; Lihong Wang; Dinggang Shen
Journal:  Neuroimage       Date:  2010-10-21       Impact factor: 6.556

8.  Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease.

Authors:  Christian Habeck; Norman L Foster; Robert Perneczky; Alexander Kurz; Panagiotis Alexopoulos; Robert A Koeppe; Alexander Drzezga; Yaakov Stern
Journal:  Neuroimage       Date:  2008-02-14       Impact factor: 6.556

Review 9.  Neuropsychological contributions to the early identification of Alzheimer's disease.

Authors:  Mark W Bondi; Amy J Jak; Lisa Delano-Wood; Mark W Jacobson; Dean C Delis; David P Salmon
Journal:  Neuropsychol Rev       Date:  2008-03-18       Impact factor: 7.444

10.  Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease.

Authors:  Mark Kilgore; Courtney A Miller; Daniel M Fass; Krista M Hennig; Stephen J Haggarty; J David Sweatt; Gavin Rumbaugh
Journal:  Neuropsychopharmacology       Date:  2009-12-09       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.